Taro Pharmaceutical Industries .(TARO) - 2024 Q2 - Quarterly Report

Financial Performance - Net sales for the quarter ended September 30, 2023, were $148.2 million, an increase from $130.5 million in the same quarter of 2022, reflecting a mid-single-digit growth when excluding a one-time gross-to-net adjustment[7] - Gross profit for the quarter was $73.6 million, representing 49.7% of net sales, compared to $47.0 million or 36.0% of net sales in the prior year quarter[7] - Operating income for the quarter was $4.7 million; excluding one-time charges, operating income was $10.9 million compared to an operating loss of $(6.8) million in the prior year[7] - Net income for the quarter was $8.5 million, compared to a net loss of $(2.8) million, resulting in earnings per share of $0.23 compared to a loss per share of $(0.07)[7] - For the six months ended September 30, 2023, net sales were $307.1 million, an increase of $19.9 million or 6.9% from $287.2 million in the same period of 2022[7] - Net income for the six months ended September 30, 2023, was $18,581 million, an increase from $11,266 million in the same period of 2022, representing a growth of 65.5%[21] Expenses - Research and development (R&D) expenses increased to $14.3 million, up $2.8 million primarily due to increased clinical studies[7] - Selling, marketing, general and administrative expenses (SMG&A) totaled $54.5 million, which included one-time charges of $6.1 million; excluding these, SMG&A was $48.4 million compared to $42.3 million in the previous year[7] Cash Flow and Liquidity - Net cash provided by operations for the six months ended September 30, 2023, was $55.3 million, compared to net cash used in operations of $37.7 million for the same period in 2022[15] - Cash and cash equivalents at the end of the period increased to $269,011 million from $175,191 million, reflecting a rise of 53.5%[21] - The company reported a decrease in trade receivables, net, of $20,927 million, compared to an increase of $2,071 million in the previous year[21] - The net cash used in investing activities was $59,866 million, compared to a net cash used of $36,039 million in the same period last year[21] - Cash paid for income taxes during the year was $6,232 million, compared to $3,091 million in the previous year, indicating an increase of 101.5%[21] Assets and Liabilities - As of September 30, 2023, cash and cash equivalents, short-term bank deposits, and marketable securities increased by $40.2 million to $1.3 billion from March 31, 2023[15] - Total assets as of September 30, 2023, were $2.12 billion, with total liabilities of $371.9 million, resulting in shareholders' equity of $1.75 billion[19] - The company reported a decrease in goodwill and intangible assets by $250 million, which was not present in the previous year[21] Investments - The company made a significant investment in marketable securities, with proceeds of $73,716 million, up from $15,516 million in the prior year[21] - The company had non-cash investing transactions for the purchase of property, plant, and equipment included in accounts payable amounting to $1,097 million[21] Exchange Rate Impact - The effect of exchange rate changes on cash and cash equivalents resulted in a decrease of $643 million[21]